Healthcare

News: FDA approved Regeneron and Sanofi’s Praluent $REGN

Healthcare, News /

Regeneron Pharmaceuticals, Inc. and Sanofi has announced that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDAapproved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of […]

News: FDA approved Regeneron and Sanofi’s Praluent $REGN Read More »

News: ZIOPHARM Drug Designated for Malignant Glioma $ZIOP

Healthcare, News /

ZIOPHARM Oncology, Inc., a bio pharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant Glioma. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression

News: ZIOPHARM Drug Designated for Malignant Glioma $ZIOP Read More »

News: CARA Leading Product Passes Test $CARA

Healthcare, News /

Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced statistically significant topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP). Uremic pruritus is a chronic

News: CARA Leading Product Passes Test $CARA Read More »